RxDoctor Payments DataLook up a doctor →

Michael McAllister, MD

Hematology & Oncology · Dothan, ALNPI 1720170053

Payments from drug & device makers

$247,668in general payments, 2019–2025

Across 886 payments — averaging $279.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astrazeneca UK Limited$173K
  • Gilead$40K
  • AstraZeneca$9K
  • Spectrum Pharmaceuticals Inc.$3K
  • Novartis$3K
  • Genentech USA, Inc.$2K
  • plus $17K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Astrazeneca UK Limited3$173,455
Gilead(2 entities)62$39,705
AstraZeneca(2 entities)40$9,056
Spectrum Pharmaceuticals Inc.7$3,234
Novartis84$2,758
Genentech USA, Inc.47$1,878
Exelixis Inc.19$1,514
Daiichi Sankyo Inc.25$1,450
Incyte Corporation24$910
Mirati Therapeutics, Inc.2$863
E.r. Squibb & Sons, L.L.C.49$852
Amgen47$665
Pfizer47$637
Bristol Myers Squibb33$626
Johnson & Johnson(2 entities)38$606
EMD Serono, Inc.5$585
ASD Specialty Healthcare, LLC9$569
Beigene USA, Inc.18$492
Astellas Pharma US Inc16$467
Regeneron Healthcare Solutions, Inc.15$448
AbbVie15$448
Puma Biotechnology, Inc.11$444
Merck24$432
Sanofi11$385
Seagen Inc.23$295
Ipsen Biopharmaceuticals, Inc10$291
Lilly USA, LLC17$274
GSK10$269
Takeda Pharmaceuticals U.S.A., Inc.13$267
Heron Therapeutics, Inc.3$251
Array Biopharma Inc17$234
Boehringer Ingelheim11$225
Eisai Inc.12$209
Beone Medicines USA, Inc.5$205
Pharmacyclics LLC, An Abbvie Company10$190
Deciphera Pharmaceuticals Inc.9$184
AVEO Pharmaceuticals, Inc.4$174
Eagle Pharmaceuticals, Inc.3$161
Genmab U.S., Inc.3$150
Bayer8$133
Taiho Oncology, Inc.2$133
Geron Corporation2$120
G1 Therapeutics, Inc.4$119
Blueprint Medicines Corporation3$98
Karyopharm Therapeutics Inc.6$96
Sun Pharmaceutical Industries Inc.1$86
Servier Pharmaceuticals LLC4$73
Rigel Pharmaceuticals, Inc.3$70
Tesaro, Inc.3$55
Acceleron Pharma, Inc.3$52
Secura Bio, Inc.3$45
Adaptive Biotechnologies Corporation3$45
Sumitomo Pharma America, Inc.3$43
Acrotech Biopharma Inc.3$43
Myovant Sciences Inc.3$42
Pharmaessentia USA Corporation2$41
Fennec Pharmaceuticals, Inc.2$40
Epizyme, Inc.2$38
Kyowa Kirin, Inc.2$36
Sobi, Inc2$36

How this compares

$247,668 in reported general payments places this provider in the 75th percentile of 177 hematology & oncology providers in Alabama.

See all hematology & oncology providers in Alabama →

Medicare billing

Part B allowed, 2024
$5,546,099
Medicare patients
878
Services billed
254,954

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Dothan

See the full list for Alabama →

Where these figures come from

Is this you, or does something look wrong? →